This project will systematically investigate the effect upon drug abuse treatment outcomes of variations in the degree of behavioral structure provided by the treatment program. The studies will be conducted in a community outpatient drug abuse treatment clinic providing opioid maintenance pharmacotherapy -- either methadone or levo-alpha- acetylmethadol (LAAM). Opioid abusers in maintenance pharmacotherapy often have high rates of nonopioid drug use, and many have the diagnosis of antisocial personality disorder (APD), which is associated with poor treatment compliance, poor treatment response, and increased HIV risk. These studies will evaluate a novel behavioral contingency procedure for enhancing compliance with concurrent nonpharmacological treatments and for improving treatment outcomes. An important secondary goal is to assess the relationship to treatment outcome of individual differences in patients' psychiatric/behavioral characteristics. In particular, we will assess the role of antisocial personality disorder and of concurrent illicit cocaine abuse as possible markers or modulators of treatment outcome. Studies 1 and 2 evaluate a behaviorally contingent pharmacotherapy procedure in which continued pharmacotherapy is contingent upon participation in the prescribed behavioral treatments. In both studies volunteer patients will be randomized to contingent versus noncontingent treatment. Study 1 will evaluate this behavioral intervention during methadone pharmacotherapy. Study 2 will evaluate the behavioral intervention during LAAM pharmacotherapy. Outcomes in the two contexts may differ because the two pharmacotherapies require different clinic visit frequencies, and this difference in behavioral structure may influence the efficacy of the behavioral contingency. Study 3 will specifically evaluate whether differences in clinic visit frequency influence treatment outcome. LAAM patients will be randomly assigned to visit the clinic 3 days versus 7 days per week. Outcome measures to be assessed in all three studies include treatment retention, attendance/participation in the behavioral treatment services urinalysis evidence of drug use, plus global clinical outcome indices such as the Addiction Severity Index. These studies will provide important information about the efficacy of the behaviorally contingent pharmacotherapy procedure, about the role of behavior structure in treatment efficacy, and about the relationship of antisocial personality and cocaine use to treatment response. The results will be valuable for guiding the development of integrated behavioral- pharmacological treatments for drug abuse and for guiding the development of effective strategies for patient-treatment matching.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Specialized Center (P50)
Project #
5P50DA005273-08
Application #
3731942
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
8
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Peirce, Jessica M; Kindbom, Kori A; Waesche, Matthew C et al. (2008) Posttraumatic stress disorder, gender, and problem profiles in substance dependent patients. Subst Use Misuse 43:596-611
Burke, Christopher K; Peirce, Jessica M; Kidorf, Michael S et al. (2008) Sleep problems reported by patients entering opioid agonist treatment. J Subst Abuse Treat 35:328-33
Wedam, Erich F; Bigelow, George E; Johnson, Rolley E et al. (2007) QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med 167:2469-75
Sigmon, Stacey C (2007) Investigating the pharmacological and nonpharmacological factors that modulate drug reinforcement. Exp Clin Psychopharmacol 15:1-20
Carroll, C Patrick; Kidorf, Michael; Strain, Eric C et al. (2007) Comparison of demographic and clinical characteristics between opioid-dependent individuals admitted to a community-based treatment setting and those enrolled in a research-based treatment setting. J Subst Abuse Treat 33:355-61
Sigmon, Stacey C; Moody, David E; Nuwayser, Elie S et al. (2006) An injection depot formulation of buprenorphine: extended bio-delivery and effects. Addiction 101:420-32
Lott, David C; Strain, Eric C; Brooner, Robert K et al. (2006) HIV risk behaviors during pharmacologic treatment for opioid dependence: a comparison of levomethadyl acetate [corrected] buprenorphine, and methadone. J Subst Abuse Treat 31:187-94
Jones, Hendree E; Fitzgerald, Heather; Johnson, Rolley E (2005) Males and females differ in response to opioid agonist medications. Am J Addict 14:223-33
Lofwall, Michelle R; Brooner, Robert K; Bigelow, George E et al. (2005) Characteristics of older opioid maintenance patients. J Subst Abuse Treat 28:265-72
Disney, Elizabeth R; Kidorf, Michael; King, Van L et al. (2005) Prevalence and correlates of cocaine physical dependence subtypes using the DSM-IV in outpatients receiving opioid agonist medication. Drug Alcohol Depend 79:23-32

Showing the most recent 10 out of 44 publications